Titan Pharmaceuticals has completed its merger with Black Titan Corporation, a Cayman Islands exempted company, and TalenTec, a Malaysian private limited company. The transaction closed successfully on October 1, 2025, making Titan a wholly owned subsidiary of Black Titan.

Commenting on the development, Chay W J, CEO of Black Titan, said, “This merger represents more than a structural change, it’s the beginning of a new chapter of innovation and global expansion. We are well-positioned to execute our strategic vision and bring transformative value to our stakeholders.”

ARC Group served as the exclusive financial advisor to Black Titan for the transaction. Titan had previously entered into a merger agreement with TalenTec (formerly known as KE) on August 19, 2024.

Headquartered in South San Francisco, California, Titan is a development-stage biopharmaceutical company formerly focused on developing proprietary therapeutics using its ProNeura long-term, continuous drug delivery technology.

Its first product based on this platform, Probuphine (buprenorphine implant), is approved in the United States, Canada, and the European Union for the maintenance treatment of opioid use disorder in clinically stable patients taking 8 mg or less of oral buprenorphine daily. Titan discontinued commercialisation of Probuphine in the US in the fourth quarter of 2020 and later sold the product in September 2023.